Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Association of Parental Dementia With Cognitive and Brain MRI Measures in Middle-Aged Adults
Neurol 73:2071-2078, 2054, Debette,S.,et al, 2009
Apolipoprotein E and Cognitive Decline in Alzheimer's Disease
Neurol 47:317-320, Plassman,B.L.&Breitner,J.C.S., 1996
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
Association Between Mid-Life Martial Status and Cognitive Function in Later Life: Population Based Cohort Study
BMJ 339:99,57, H�kansson,K.,et al, 2009
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Joint Effect of Stroke and APOE 4 on Dementia Risk: The Canadian Study of Health and Aging
Neurol 70:9-16,5, Jin,Y.P.,et al, 2008
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Donepezil Preserves Cognition and Global Function in Patients With Severe Alzheimer Disease
Neurol 69:459-469, Black,S.E.,et al, 2007
Mild Cognitive Impairment
Lancet 367:1262-1270, Gauthier,S.,et al, 2006
Bone Mineral Density and the Risk of Alzheimer Disease
Arch Neurol 62:107-111, Tan,Z.S.,et al, 2005
Unawareness of Cognitive Deficit (Cognitive Anosognosia) in Probable AD and Control Subjects
Neurol 64:693-699, Barrett, A.M., et al, 2005
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
NEJM 346:476-483, 466, Seshadri,S.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Age-Related Memory Decline
Arch Neurol 58:360-364, Small,S.A., 2001
Hormone Replacement Therapy and Cognition
JAMA 285:1489-1499, LeBlanc,E.S.,et al, 2001
High-Dose Estradiol Improves Cognition for Women with AD, Results of a Randomized Study
Neurol 57:605-612, Asthana,S.,et al, 2001
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease
JAMA 283:1007-1015,1055, Mulnar,R.A.,et al, 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
Mild Cognitive Impairment, Clinical Characterization and Outcome
Arch Neurol 56:303-308, Petersen,R.C.,et al, 1999
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
The APOE-e4 Allele and the Risk of Alzheimer Disease Among AFrican Americans, Whites and Hispanics
JAMA 279:751-755, 7881998., Tang,M.,et al, 1998
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
The Genetics of Alzheimer Disease, Current Status and Future Prospects
Arch Neurol 55:294-296, Blacker,D.&Tanzi,R.E., 1998
Estrogen Therapy in Postmenopausal Women, Effects on Cognitive Function and Dementia
JAMA 279:688-695, Yaffe,K.,et al, 1998
Smoking and Risk of Dementia and Alzheimer's Disease in a Population-Based Cohort Study:The Rotterdam Study
lancet 351:1840-1843, Ott,A.,et al, 1998
The Efficacy of Ginkgo Biloba on Cognitive Function in Alzheimer Disease
Arch Neurol 55:1409-1415, Oken,B.S.,et al,, 1998
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
JAMA 277:825-831, Lendon,C.L.,et al, 1997